• OHMX.bio and Fujirebio Europe Receive Grant of 720K EURO to Incorporate Third Generation Sequencing into Clinical In Vitro Diagnostics Platform

    Tuesday December 8th 2020

  • Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Thursday December 3rd 2020

  • reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

    Thursday December 3rd 2020

  • eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

    Wednesday December 2nd 2020

  • AbolerIS Pharma signed with Ouest Valorisation an exclusive world-wide license to develop new first-in-class anti-CD45RC monoclonal antibodies

    Wednesday December 2nd 2020

  • atbtherapeutics initiates agreement with iBio CDMO to manufacture game-changer atbodies to better treat cancer

    Tuesday December 1st 2020

  • Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial

    Tuesday December 1st 2020

  • Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers

    Tuesday December 1st 2020

  • Your news here?

  • Mithra's exclusivity on Estetrol applications extended to 2036 in Europe

    Tuesday December 1st 2020

  • flanders.bio job board increasingly popular

    Thursday November 26th 2020

  • Estetrol recognized as a "New Active Substance" by the European Medicines Agency (EMA)

    Wednesday November 25th 2020


Strategic Partners